Summary of BMS Q4 2025 and Full Year Performance Company Overview - The document discusses Bristol-Myers Squibb (BMS), a major player in the pharmaceutical industry, focusing on its Q4 2025 and full-year performance metrics. Key Financial Metrics - **Q4 2025 Revenue**: BMS achieved revenue of $12.5 billion, with growth portfolio sales at $7.4 billion (+15%) and legacy portfolio sales at $5.1 billion (-16%) [1] - **Full Year 2025 Revenue**: Total revenue for 2025 was $48.2 billion (-1%), with growth portfolio sales at $26.4 billion (+17%) and legacy portfolio sales at $21.8 billion (-16%) [1] 2026 Revenue Guidance - BMS updated its 2026 revenue guidance to a range of $46 billion to $47.5 billion (-5% to -1%) [2] - Non-GAAP EPS guidance was set between $6.05 and $6.35 per share [2] Product Performance Highlights Oncology - **Opdivo (Nivolumab)**: Sales reached $2.69 billion (+7%), driven by volume growth and new approvals [2] - **Yervoy (Ipilimumab)**: Sales were $810 million (+18%) [2] - **Opdualag**: Sales of $350 million (+37%), with a 30%+ market share in 1L melanoma in the US [2] Hematology - **Revlimid (Lenalidomide)**: Sales dropped to $600 million (-55%) due to generic competition [2] - **Pomalyst**: Sales were $690 million (-16%) [2] - **Reblozyl**: Sales increased to $670 million (+21%), driven by demand for 1L treatment of MDS-related anemia [2] - **Breyanzi**: Sales reached $390 million (+47%), primarily driven by demand in LBCL [2] Cardiovascular - **Eliquis (Apixaban)**: Sales were $3.45 billion (+6%), with US and ex-US sales growing by 4% and 9% respectively; 2026 global revenue growth is expected at 10% to 15% [3] - **Camzyos**: Sales of $350 million (+57%) [3] - **Milvexian**: Phase 3 clinical study terminated due to interim analysis not meeting efficacy [3] Immunology - **Orencia (Abatacept)**: Sales remained stable at $1.01 billion [3] - **Sotyktu**: Sales of $86 million (+3%), with a PDUFA date for PsA indication set for March 6, 2026 [3] Neurology - **Cobenfy**: Sales of $51 million [3] - **Zeposia**: Sales of $160 million (-1%), primarily contributed by MS indication [3] Additional Insights - The document highlights the impact of generic competition on legacy products and the growth potential in the growth portfolio, particularly in oncology and cardiovascular segments [2][3] - The anticipated decline in revenue for Eliquis in 2027 is noted, with a projected drop of $1.5 billion to $2 billion [3]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [32]. Core Insights - Eli Lilly's total revenue for 2025 is projected to reach $65.179 billion, representing a significant year-on-year growth of 45%. The revenue for 2026 is expected to be between $80 billion and $83 billion. The two key products, Tirzepatide, are anticipated to contribute a combined global sales of $36.5 billion, with the diabetes version Mounjaro generating $22.965 billion (up 99% year-on-year) and the weight loss version Zepbound achieving $13.542 billion (up 175% year-on-year) [3]. - Eli Lilly's drug approval progress for 2025 includes the FDA approval of the multi-dose prefilled pen for Tirzepatide and the approval of a new indication for the drug Jaypirca. Applications for obesity indications of Orforglipron have been submitted to U.S. and Japanese regulatory agencies, along with submissions to the EU for both obesity and type 2 diabetes indications [3]. - The pipeline progress for Eli Lilly in 2025 includes positive results from Phase 3 clinical trials for the combination of Taltz and Tirzepatide in adult patients with active psoriatic arthritis and obesity. Orforglipron has shown positive clinical results in studies transitioning from injectable to oral incretin therapy, and Retatrutide has also shown positive results in studies involving obesity with knee osteoarthritis [3]. Summary by Sections Industry Overview - The biopharmaceutical industry is rated as stronger than the market, maintaining a positive outlook [3][4]. - The investment strategy emphasizes the increasing global competitiveness of Chinese innovative pharmaceutical companies, focusing on potential therapeutic areas such as metabolic diseases, chronic diseases, and central nervous system disorders [4]. Market Performance - The pharmaceutical sector saw a slight increase of 0.14% last week, while the Shanghai and Shenzhen 300 Index decreased by 1.33%. The pharmaceutical industry ranked 14th among 28 industries in terms of performance [8][18]. - The valuation of the pharmaceutical sector is currently at 29.57 times (TTM), with a premium of 10.50% over the overall A-shares excluding financials [23]. Notable Company Developments - Cloudtop announced the approval of Velsipity® for treating moderate to severe ulcerative colitis in China, marking a significant advancement in treatment options [12]. - BMS reported a total revenue of $48.194 billion for 2025, with the drug Opdivo generating $10.049 billion, reflecting an 8% increase [13]. - Innovent Biologics achieved a total product revenue of approximately 11.9 billion yuan for 2025, maintaining a strong growth rate of about 45% [15]. - Saintin Biotech announced a strategic collaboration with Genentech for RNAi drug development, highlighting ongoing innovation in the sector [16].